Research and practice in thrombosis and haemostasis · 2026
Analytical validity of the INNOVANCE Antithrombin assay for the measurement of antithrombin activity at fitusiran clinical decision points.
СтатьяВалидационное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Freidel Christoph, Boehm-Weigert Martina, Dahler Christine, Demissie Marek, Wang Hong, Liu Mingjie, Ali Shariq, Chhabra Ekta Seth
Аннотация
BACKGROUND: Fitusiran is an antithrombin (AT)-lowering therapy for hemophilia A and B, with dosing individually adjusted to maintain AT activity between 15% and 35%. The therapy, therefore, requires an AT activity assay with high analytical sensitivity and precision, especially at the lower end of the measuring range (≤20%).
OBJECTIVES: This study evaluated the analytical performance characteristics of the INNOVANCE Antithrombin assay at the low end of the measuring range and assessed equivalence between different analyzers.
METHODS: Performance data were generated on various analyzers from Siemens Healthineers according to Clinical and Laboratory Standards Institute guidelines, including limit of quantification (LoQ), interferences, and precision. System comparability was evaluated using samples from patients treated with fitusiran.
RESULTS: This study demonstrated high precision and reproducibility of results across reagent lots and systems with <10% coefficient of variation at 10% and 15% AT activity on all analyzers, except for the BCS XP system at the 10% AT level, with a repeatability coefficient of variation of 13.94%. Diluted control plasma showed similar precision characteristics to native samples and good recovery of expected AT value. Therapeutics potentially being used by the hemophilia population were demonstrated to not interfere with the assay. LoQ was shown to be ≤8.78% of normal on all analyzers. System comparability was confirmed with correlation coefficients of ≥0.997, slopes between 0.976 and 1.005, and intercepts between 0.5% and 2.1% of normal.
CONCLUSION: The study confirms the INNOVANCE Antithrombin assay can precisely and reliably quantify AT activity at fitusiran clinical decision points and further supports its suitability for clinical management of people on fitusiran prophylaxis.
OBJECTIVES: This study evaluated the analytical performance characteristics of the INNOVANCE Antithrombin assay at the low end of the measuring range and assessed equivalence between different analyzers.
METHODS: Performance data were generated on various analyzers from Siemens Healthineers according to Clinical and Laboratory Standards Institute guidelines, including limit of quantification (LoQ), interferences, and precision. System comparability was evaluated using samples from patients treated with fitusiran.
RESULTS: This study demonstrated high precision and reproducibility of results across reagent lots and systems with <10% coefficient of variation at 10% and 15% AT activity on all analyzers, except for the BCS XP system at the 10% AT level, with a repeatability coefficient of variation of 13.94%. Diluted control plasma showed similar precision characteristics to native samples and good recovery of expected AT value. Therapeutics potentially being used by the hemophilia population were demonstrated to not interfere with the assay. LoQ was shown to be ≤8.78% of normal on all analyzers. System comparability was confirmed with correlation coefficients of ≥0.997, slopes between 0.976 and 1.005, and intercepts between 0.5% and 2.1% of normal.
CONCLUSION: The study confirms the INNOVANCE Antithrombin assay can precisely and reliably quantify AT activity at fitusiran clinical decision points and further supports its suitability for clinical management of people on fitusiran prophylaxis.